You are viewing: Australia Biobanking Market analysis
Part of: Biobanking Market (Global)

The Australia Biobanking Market was valued at $60.6 Million in 2025 and projected to reach to $86.6 Million by 2030, representing a compound annual growth rate of 7.4%. Australia's biobanking market is positioned for sustained growth driven by increasing adoption of personalized healthcare solutions and precision medicine initiatives.

Australia Biobanking Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Australia Biobanking Market Trends and Insights

  • Australia's biobanking sector is driven by increasing investment in precision medicine, growing demand for personalized healthcare solutions, and strengthening regulatory frameworks that support sample collection and storage.
  • Australia's position as a developed healthcare economy with advanced research infrastructure positions it as a key player in the Asia Pacific biobanking landscape. The Australian biobanking market benefits from robust government funding for medical research, expanding clinical trial activities, and rising adoption of genomic technologies across healthcare institutions.
  • Australia's commitment to biomedical innovation and collaborative research initiatives supports market expansion throughout the forecast period.
  • Australia's biobanking infrastructure continues to evolve with enhanced data management systems and improved sample quality standards, attracting both domestic and international research partnerships..

Key Market Statistics

  • CAGR (2025-2030) 7.4% CAGR
  • Market Size, 2025 ~USD 60.6 Million
  • Forecast, 2030 ~USD 86.6 Million
  • Country Australia

Australia Biobanking Market Overview

Market Valuation Growth :

Australia's biobanking market is valued at $60.6 million in 2025, with a projected CAGR of 7.4% through 2030, reaching $86.6 million. This steady growth trajectory reflects increasing healthcare investments and infrastructure development across the country.

Precision Medicine Adoption :

Australian healthcare institutions are increasingly investing in precision medicine initiatives, driving demand for advanced biobanking solutions. This shift enables personalized treatment approaches and improved patient outcomes across major medical centers and research facilities.

Regulatory Framework Strengthening :

Australia's evolving regulatory environment supports biobanking operations through enhanced guidelines for sample collection, storage, and data management. These frameworks ensure compliance and build confidence among healthcare providers and research institutions in biobanking infrastructure.

Developed Healthcare Infrastructure :

As a developed nation, Australia possesses advanced healthcare systems and research capabilities that support biobanking expansion. Strong institutional partnerships and government backing facilitate investment in state-of-the-art biobanking facilities and technologies.

Australia Biobanking Market Dynamics

  • Healthcare providers and research institutions are investing in advanced biobanking infrastructure to support genomic research and clinical applications.
  • The strengthening regulatory framework provides a stable foundation for market expansion, encouraging both public and private sector participation in biobanking development. Looking ahead, Australia's biobanking sector will benefit from growing collaboration between academic institutions, hospitals, and biotechnology companies.
  • Increased government funding for medical research and rising patient awareness of personalized medicine will further accelerate market growth.
  • The market's 7.4% CAGR reflects Australia's commitment to advancing healthcare innovation and establishing itself as a regional leader in biobanking capabilities..

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Key Takeaways

    • Australia's biobanking market is valued at $60.6 million in 2025 and expected to reach $86.6 million by 2030, representing a 7.4% CAGR.
    • Australia's market growth is supported by increased government funding for medical research and expanding precision medicine initiatives.
    • Australia's advanced healthcare infrastructure and regulatory environment create favorable conditions for biobank development and international collaboration.
    • Australia's biobanking sector is experiencing rising demand from clinical trials, genomic research, and personalized medicine applications.

    Biobanking Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment SOFTWARE (Offering)
    Forecast Period 2025–2030
    Growth Rate CAGR of 9.1% from 2025 to 2030
    Largest Segment PRODUCTS (Offering)
    Market Size Base Year (Billions) ~USD 7.65 (2025)
    Revenue Forecast (Billions) ~USD 11.82 (2030)
    Segments Covered Offering, Type, Operation Type, Workflow, Sample Type, Ownership, Application, End User

    Australia Biobanking Market Report Segmentation

    8 segment dimensions are covered across the global market.

    By Offering

    • Products
    • Services
    • Software

    By Type

    • Alarm & Monitoring Systems
    • Clinical Research
    • Consumables
    • Cryogenic Storage Systems
    • Equipment
    • Freezers & Refrigerators
    • Life Science Research
    • Life Sciences Research
    • Other Equipment & Accessories
    • Other Services
    • Physical Biobanking Services
    • Temperature & Humidity Control Systems
    • Thawing Equipment
    • Virtual Biobanking Services

    By Operation Type

    • Automated Equipment
    • Automated Operations
    • Manual Equipment
    • Manual Operations

    By Workflow

    • Sample Analysis
    • Sample Collection & Storage
    • Sample Processing
    • Transport & Logistics

    By Sample Type

    • Biological Fluids
    • Blood Products
    • Human Waste Products
    • Nucleic Acids
    • Solid Tissues & Organs
    • Stem Cells & Cell Lines

    By Ownership

    • Academic & Research Institution Biobanks
    • Hybrid/Ppp Model
    • National/Regional Agencies
    • Other Ownership Models
    • Private/ Commercial Biobanks

    By Application

    • Diagnostic Applications
    • Other Applications
    • Research Applications
    • Therapeutic Applications

    By End User

    • Academic & Research Institutes
    • Biobanks
    • Cros
    • Hospitals & Diagnostic Laboratories
    • Pharma-Biotech Companies & Cros

    AUSTRALIA: BIOBANKING SERVICES MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    ACADEMIC & RESEARCH INSTITUTES7.57.78.399.810.711.812.99.4
    HOSPITALS & DIAGNOSTIC LABORATORIES4.84.95.35.76.26.77.48.19
    PHARMA-BIOTECH COMPANIES & CROS1818.52021.823.926.228.931.89.7
    TOTAL30.331.133.536.539.943.74852.89.5

    AUSTRALIA: BIOBANKING PRODUCTS MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    BIOBANKS43.844.64750.153.757.862.467.77.6
    CROS12.81313.614.415.316.417.6196.9
    TOTAL56.757.660.664.56974.28086.67.4

    Target Audience

    • Healthcare Providers & Hospital Networks : Australian hospitals and healthcare networks need market intelligence to develop biobanking capabilities and integrate precision medicine services. This data supports infrastructure investment decisions and strategic planning for personalized healthcare delivery.
    • Biotech & Diagnostics Companies : Biotech firms and diagnostic companies operating in Australia require market insights to identify growth opportunities and develop targeted solutions. Understanding market size, growth rates, and regulatory requirements is critical for market entry and expansion strategies.
    • Research Institutions & Universities : Australian academic and research institutions need market data to secure funding, establish biobanking facilities, and collaborate with industry partners. Market projections support grant applications and strategic research planning initiatives.
    • Government & Policy Makers : Australian health authorities and policymakers require market analysis to inform healthcare policy, allocate research funding, and develop regulatory frameworks. This data supports evidence-based decision-making for biobanking infrastructure development.
    • Investors & Private Equity Firms : Investment firms evaluating opportunities in Australian healthcare need comprehensive market data on biobanking growth potential, CAGR trends, and competitive landscape. This intelligence informs investment decisions and portfolio development in the healthcare sector.

    Key Companies in the Australia Biobanking Market

    CompanyHQOwnershipStrongest segments
    MAXCYTE, INCUnited StatesPublic CompanyExPERT ATx and STx instruments,ExPERT GTx and VLx instruments,Disposable processing assemblies (PAs),
    HDFC BANKIndiaPublic CompanyRetail Banking (deposits, consumer and home loans, cards),Wholesale Banking (corporate, SME, supply chain, trade),Treasury and Markets (money market, derivatives, investments),
    STANDARD CHARTEREDUnited KingdomPrivate CompanyFinancial Markets (FX, rates, commodities, credit),Transaction Banking (trade, cash, liquidity, custody),Corporate & Structured Finance,
    YES BANKIndiaPublic CompanyRetail banking (deposits, cards, consumer loans),Corporate and wholesale banking,MSME and business banking,
    CHOLAMANDALAM INVESTMENT AND FINANCE COMPANY LIMITEDIndiaPublic CompanyVehicle Finance (CV, PV, 2W/3W, tractors, construction equipment),Loan Against Property (LAP) and SME Secured Loans,Home Loans and Home Extensions,
    AXIS MUTUAL FUNDIndiaPrivate CompanyActively managed equity funds,Hybrid and asset allocation funds,Debt and money market funds,
    THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLife Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
    PHC HOLDINGS CORPORATIONJapanPublic CompanyDiabetes Management,Diagnostic and Life Sciences,Healthcare Solutions (EMR, billing, pharmacy, wellness),
    QIAGENNetherlandsPublic CompanySample technology consumables and instruments,Immune response and infectious disease diagnostics,Oncology and sexual & reproductive health assays,
    MERCK KGAAGermanyPublic CompanyLife Science (reagents, consumables, bioprocessing, CDMO/testing),Healthcare (prescription drugs and biopharmaceuticals),Electronics (semiconductor and display materials, specialty gases, equipment),
    AVANTOR, INC.United StatesPublic CompanyMaterials and consumables,Equipment and instrumentation,Services and specialty procurements,
    CRYOPORTUnited StatesPublic CompanyLife Sciences Services (logistics, biostorage, bioservices, consulting),Life Sciences Products (cryogenic freezers, dewars, accessories),IoT and digital monitoring solutions,
    AGILENT TECHNOLOGIES, INC.United StatesPublic CompanyLife Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets,
    LABCORPUnited StatesPublic CompanyRoutine and chronic-disease diagnostics (chemistry, hematology, A1C, thyroid, PSA, urinalysis),Specialty and esoteric testing (gene-based, oncology, cardiovascular, endocrinology, infectious disease),Biopharma Laboratory Services and clinical trial support,
    EUROFINS SCIENTIFICLuxembourgPublic CompanyFood and Feed Testing,Environment Testing,Biopharma and Clinical Diagnostics,
    HAIER BIOMEDICALChinaPublic CompanyULT freezers and low-temperature storage,Pharmacy and vaccine refrigerators/freezers, cold rooms,Blood bank and transfusion chain equipment,
    HAMILTON COMPANYUnited StatesPublic Investment FirmFund-of-funds (primary and secondary),Direct credit,Direct and co-investments / buyouts,

    MAXCYTE, INC

    MAXCYTE, INC is a public company based in the United States that was founded in 1998 and currently employs 91 people.

    HDFC BANK

    HDFC BANK is a public company based in India that was founded in 1994 and currently employs 212,958 people.

    STANDARD CHARTERED

    STANDARD CHARTERED is a private company based in the United Kingdom that was founded in 1853 and currently employs 66,524 people.

    YES BANK

    YES BANK is a public company based in India that was founded in 2003 and currently employs 29,577 people.

    CHOLAMANDALAM INVESTMENT AND FINANCE COMPANY LIMITED

    CHOLAMANDALAM INVESTMENT AND FINANCE COMPANY LIMITED is a public company based in India that was founded in 1978 and currently employs 51,320 people.

    AXIS MUTUAL FUND

    AXIS MUTUAL FUND is a private company based in India that was founded in 2009.

    THERMO FISHER SCIENTIFIC INC.

    THERMO FISHER SCIENTIFIC INC. is a public company based in the United States that was founded in 1956 and currently employs 125,000 people.

    PHC HOLDINGS CORPORATION

    PHC HOLDINGS CORPORATION is a public company based in Japan that was founded in 1948 and currently employs 8,647 people.

    QIAGEN

    QIAGEN is a public company based in the Netherlands that was founded in 1984 and currently employs 5,500 people.

    MERCK KGAA

    MERCK KGAA is a public company based in Germany that was founded in 1668 and currently employs 59,077 people.

    AVANTOR, INC.

    AVANTOR, INC. is a public company based in the United States that was founded in 1904 and currently employs 13,500 people.

    CRYOPORT

    CRYOPORT is a public company based in the United States that was founded in 1999 and currently employs 688 people.

    AGILENT TECHNOLOGIES, INC.

    AGILENT TECHNOLOGIES, INC. is a public company based in the United States that was founded in 1999 and currently employs 18,000 people.

    LABCORP

    LABCORP is a public company based in the United States that was founded in 1995 and currently employs 66,385 people.

    EUROFINS SCIENTIFIC

    EUROFINS SCIENTIFIC is a public company based in Luxembourg that was founded in 1987 and currently employs 65,694 people.

    HAIER BIOMEDICAL

    HAIER BIOMEDICAL is a public company based in China that was founded in 2005 and currently employs 2,945 people.

    HAMILTON COMPANY

    HAMILTON COMPANY is a public investment firm based in the United States that was founded in 1991 and currently employs 785 people.

    Reasons to Buy this Report

    • Market Size & Growth Projections : Access detailed valuation data showing Australia's biobanking market at $60.6M (2025) growing to $86.6M (2030). Understand market dynamics and growth drivers specific to the Australian healthcare landscape for accurate forecasting and investment planning.
    • Regulatory Landscape Analysis : Gain insights into Australia's strengthening regulatory frameworks governing biobanking operations. Understand compliance requirements, sample collection standards, and data management protocols essential for market entry and operational success in Australia.
    • Competitive Positioning Strategy : Identify key market opportunities and competitive gaps within Australia's biobanking sector. Benchmark against regional developments and understand how to position products and services to capture market share in this growing healthcare segment.
    • Investment & Partnership Opportunities : Discover institutional partnerships, government funding initiatives, and investment trends specific to Australian biobanking. Identify collaboration opportunities with research institutions, hospitals, and biotechnology companies driving market expansion.
    • Precision Medicine Integration : Understand how Australian healthcare providers are integrating biobanking with precision medicine initiatives. Learn about demand drivers for personalized healthcare solutions and align your offerings with emerging clinical and research requirements.

    Frequently asked questions

    What is the current size of Australia's biobanking market?

    Australia's biobanking market was valued at $60.6 million in 2025 and is projected to grow to $86.6 million by 2030.

    What is the growth rate of Australia's biobanking market?

    Australia's biobanking market is expected to grow at a compound annual growth rate (CAGR) of 7.4% from 2025 to 2030.

    What factors are driving growth in Australia's biobanking market?

    Australia's biobanking market growth is driven by increased investment in precision medicine, government funding for medical research, expanding clinical trials, and rising adoption of genomic technologies.

    How does Australia's biobanking market compare to the Asia Pacific region?

    Australia represents a significant developed market within Asia Pacific, with advanced healthcare infrastructure and regulatory frameworks supporting biobanking operations and international research collaborations.

    What opportunities exist in Australia's biobanking sector?

    Australia's biobanking sector offers opportunities in precision medicine development, genomic research expansion, clinical trial support, and international partnerships leveraging Australia's research capabilities.

    RESEARCH METHODOLOGY

    This study involved four major activities to estimate the current size of the biobanking market. Exhaustive secondary research was conducted to gather information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the total market size. Following this, data triangulation was used to estimate the market size of segments and subsegments.

    Secondary Research

    Secondary research was primarily used to identify and gather information for the extensive, technical, market-oriented, and commercial study. Secondary sources for this study included publications from government sources, such as the European, Middle Eastern & African Society for Biopreservation and Biobanking (ESBB), Biobanking and BioMolecular Resources Research Infrastructure - European Research Infrastructure Consortium (BBMRI-ERIC), International Society for Biological and Environmental Repositories (ISBER), National Institutes of Health (NIH), and the US Food and Drug Administration (US FDA), as well as ScienceDirect and several others. Secondary sources also included corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. These sources were used to obtain key information on major players, global product revenues, market classification, and segmentation by industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary data were collected and analyzed to determine the overall size of the global Biobanking market, and the findings were validated through primary research.

    Primary Research

    In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among others, to obtain and verify critical qualitative and quantitative information and to assess market prospects. Primary sources from both the supply and demand sides of the market were interviewed to gather qualitative and quantitative data. The following is a breakdown of the primary respondents:

    Biobanking Market Size, and Share

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The global size of the biobanking market was estimated using multiple approaches. A detailed market estimation approach was used to estimate and validate the market value and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    Biobanking Market : Top-Down and Bottom-Up Approach

    Biobanking Market Top Down and Bottom Up Approach

    Data Triangulation

    After estimating the overall market size through the market size estimation process, the total market was divided into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, the data triangulation procedure was employed; it involved analyzing various factors and trends from both the demand and supply sides.

    Market Definition

    Biobanking involves collecting, processing, storing, and managing biological samples—such as blood, tissues, stem cells, nucleic acids, and other human-derived materials—for research, diagnostic, and therapeutic applications. The market includes equipment, consumables, software, and services used by CROs, biobanks, pharmaceutical and biotechnology companies, and academic and research institutions. These entities manage diverse sample types, including blood products, human tissues, stem cells and cell lines, nucleic acids, biological fluids, and human waste products, using manual or automated systems depending on technological adoption. The market is also segmented by ownership models, including academic and research institutions, national and regional agencies, private organizations, and other entities.

    Key Stakeholders

    • Academic & Research Institutes
    • Biobanks
    • Contract Research Organizations (CROs)
    • Market Research and Consulting Firms
    • Pharmaceutical and Biotechnology Companies
    • Regulatory Agencies
    • Venture Capitalists
    • Forensics Labs
    • Government organizations
    • Private research firms
    • Hospitals and Diagnostic Laboratories

    Report Objectives

    • To define, describe, and forecast the biobanking market by offering, equipment-operation type, service-ownership, product-sample type, application, product-end user, service-end user, and region
    • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
    • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall biobanking market
    • To analyze opportunities for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to six regions: North America (US and Canada), Europe (Germany, France, the UK, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), Latin America (Brazil, Mexico, Argentina, and the Rest of Latin America), the Middle East [GCC Countries (Saudi Arabia (KSA), United Arab Emirates (UAE), and the Rest of GCC Countries) and the Rest of Middle East], and Africa
    • To profile the key players and analyze their market share and core competencies
    • To analyze competitive developments, such as product launches, partnerships, agreements, collaborations, and expansions
    • To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy

    Available customizations:

    With the given market data, MarketsandMarkets offers customization as per the company’s specific needs. The following options are available for the report:

    Geographical Analysis

    • Further breakdown of Rest of Europe biobanking market, by country
    • Further breakdown of Rest of Asia Pacific biobanking market, by country

    Comapany Information

    • Detailed analysis and profiling of additional market players (up to five)

    Segment Analysis

    • Cross-segment analysis

     

    Get the Full Biobanking Market Report

    Full forecast, segment splits, and company analysis for all Biobanking Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status